Applied Dna Sciences Inc (NASDAQ:BNBX – Get Free Report) was the recipient of a large decrease in short interest in June. As of June 15th, there was short interest totaling 55,360 shares, a decrease of 60.5% from the May 31st total of 140,122 shares. Approximately 0.8% of the company’s stock are sold short. Based on an average daily volume of 236,645 shares, the short-interest ratio is currently 0.2 days.
Applied Dna Sciences Stock Up 0.2%
Shares of NASDAQ:BNBX opened at $0.35 on Wednesday. The business’s 50-day simple moving average is $0.46. Applied Dna Sciences has a one year low of $0.32 and a one year high of $7.15. The company has a market cap of $2.52 million, a PE ratio of -0.01 and a beta of 0.52.
Applied Dna Sciences (NASDAQ:BNBX – Get Free Report) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.68) EPS for the quarter. The business had revenue of $1.02 million for the quarter. Applied Dna Sciences had a negative return on equity of 349.95% and a negative net margin of 1,647.25%.
Analyst Upgrades and Downgrades
View Our Latest Report on Applied Dna Sciences
Applied Dna Sciences Company Profile
Applied DNA Sciences is a U.S.-based biotechnology company that develops and commercializes molecular-level solutions for product authentication, supply chain security and forensic identification. The company’s technologies apply unique DNA markers and laboratory testing methods to tag, track and verify the authenticity of goods and materials, with the goal of combating counterfeiting, diversion and fraud across complex supply chains.
Central to Applied DNA’s offering is a suite of proprietary DNA-based markers and associated assays that can be incorporated into inks, fibers, coatings and other substrates to create tamper-evident, forensic-grade identifiers.
Featured Articles
- Five stocks we like better than Applied Dna Sciences
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for Applied Dna Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Dna Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
